Table of contents
- Trial overview
- Who was studied
- Treatments compared
- What was measured
- Trial design and phase
- What the trial means for patients
Trial overview
The main trial in the data is THE ANTES B+ STUDY, an open-label, pragmatic, randomized, controlled trial in people with chronic obstructive pulmonary disease (COPD). It studied whether triple therapy works better than LABA-LAMA combination treatment for improving clinical control in high-risk GOLD B patients. The study was completed and included 1,028 participants.[1]
The trial is described as interventional, which means researchers assigned treatments and then measured outcomes over time. It was also open-label, meaning both the study team and the participants knew which treatment was being used.[1]
Who was studied
The target population was people with COPD, a long-term lung disease that makes breathing difficult. More specifically, the study focused on high-risk GOLD B+ patients, which is the group the trial used to define its patient population.[1]
The trial data do not give a full list of inclusion or exclusion rules, but they clearly show that this study was designed for COPD patients who fit the GOLD B+ risk profile. This makes the study relevant to people with more complex COPD who need close follow-up.[1]
Treatments compared
The main comparison was between Trelegy® and LABA-LAMA treatment. The brief summary states that the study wanted to test the efficacy of Trelegy® versus LABA-LAMA treatment in improving clinical control in COPD B+ patients.[1]
The intervention list also includes many inhaled products used as comparators or related treatments in the study record, including products such as Onbrez Breezhaler, Ultibro Breezhaler, Seebri Breezhaler, Spiriva, ANORO ELLIPTA, and others. The trial data do not explain each product in detail, but they show that the study compared real-world inhaled COPD treatment options.[1]
What was measured
The main outcome was whether there was an association between treatment and being persistently controlled by clinical control at all study visits. To count as controlled, a participant had to meet the clinical control criteria at month 3, 6, 9, and 12.[1]
The study also describes clinical control (CC) as a validated composite endpoint. That means the result is made from more than one part, here called stability and impact, so the trial looked at both how steady the disease was and how much it affected the patient.[1]
The brief summary repeats the same goal: to test whether Trelegy® or LABA-LAMA treatment improves clinical control in COPD B+ patients. This shows that the central question of the study was not just symptom relief at one visit, but ongoing control across the full study period.[1]
Trial design and phase
This was a Phase 3 trial, which is a late-stage study usually done in larger groups of patients. Phase 3 studies often compare treatments in a more practical setting to see how well they work in everyday care.[1]
The study was randomized, meaning participants were assigned to treatment groups by chance. It was also controlled, which means one treatment was compared against another treatment rather than being studied alone.[1]
The trial was also pragmatic, which means it was designed to reflect real clinical practice as much as possible. This type of design helps show how a treatment may perform in routine care, not only in a very strict research setting.[1]
What the trial means for patients
For patients, this trial asks a simple but important question: which inhaled treatment plan helps people with COPD stay controlled over time? The study focuses on people with higher-risk disease, so its results are most relevant to patients who need ongoing management and follow-up.[1]
The trial does not report detailed symptom scores, lung function numbers, or safety results in the provided data. Based on the available information, the main value of the study is that it compares treatment strategies using a patient-centered outcome: staying controlled across several visits over 12 months.[1]
